title: Treatment of deep vein thrombosis using temporary vena caval filters after allogeneic bone marrow transplantation.
abstract: Bone marrow transplant (BMT) recipients have risk factors for deep vein thrombosis (DVT) including venous stasis caused by immobilization in the sterile unit, vessel wall damage caused by preparative regimen or indwelling catheters, and hypercoagulability caused by decreased natural anticoagulants. We successfully treated a patient who developed massive DVT in the superior vena cava after BMT with anticoagulation and the use of temporary vena caval filters. Considering the delayed complications, permanent filter is not appropriate for BMT recipients, because the risk factors for DVT associated with BMT are transient. We considered that temporary vena caval filter is a safe and useful device to prevent pulmonary embolism after DVT in BMT recipients.
authors.affiliation: Department of Hematology, International Medical Center of Japan, Tokyo. ycanda-tky@umin.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: R
authors.initials: R
authors.lastname: Yamamoto
authors.forename: A
authors.initials: A
authors.lastname: Chizuka
authors.forename: M
authors.initials: M
authors.lastname: Suguro
authors.forename: T
authors.initials: T
authors.lastname: Hamaki
authors.forename: T
authors.initials: T
authors.lastname: Matsuyama
authors.forename: N
authors.initials: N
authors.lastname: Takezako
authors.forename: A
authors.initials: A
authors.lastname: Miwa
authors.forename: A
authors.initials: A
authors.lastname: Togawa
authors.forename: M
authors.initials: M
authors.lastname: Kume
authors.forename: M
authors.initials: M
authors.lastname: Tsukuda
authors.forename: K
authors.initials: K
authors.lastname: Hasuo
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002405:Catheterization, Central Venous / Q000009:adverse effects; D020147:Coagulation Protein Disorders / Q000150:complications; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004730:Endothelium, Vascular / Q000293:injuries; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007103:Immobilization / Q000009:adverse effects; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D011859:Radiography; D016879:Salvage Therapy; D019851:Thrombophilia / Q000209:etiology; D014184:Transplantation, Homologous; D016306:Vena Cava Filters; D014683:Vena Cava, Superior / Q000000981:diagnostic imaging / Q000473:pathology; D020246:Venous Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014750:Vincristine; D014859:Warfarin; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D006493:Heparin; D008558:Melphalan